Jazz Pharmaceuticals Announces Pricing of $1.1 Billion Private Offering of Exchangeable Senior Notes

Jazz Pharmaceuticals announced an upsized $1.1 billion private offering of exchangeable senior notes due 2032, according to Market Screener. The notes carry a 1.875% interest rate and will mature on September 15, 2032, unless exchanged earlier. The sale is expected to close on August 31, 2026.
Investors can exchange the notes at an initial rate of 2.8150 ordinary shares per $1,000 principal amount, representing a 42.5% premium above the stock's last reported price on August 26, 2025, Barchart reported. Jazz Pharmaceuticals will fully guarantee the notes on a senior unsecured basis.
The notes accrue interest at a 1.875% annual rate, paid twice yearly on March 15 and September 15. Holders can convert their notes into Jazz ordinary shares at the preset exchange rate of 2.8150 shares per $1,000 of principal, PR Newswire noted. The company set this rate 42.5% above the market price to give investors upside potential if the stock rises.
If Jazz Pharmaceuticals faces certain tax-related events, the company can redeem all or part of the notes before maturity. This tax redemption clause protects Jazz from unexpected tax burdens that might otherwise erode shareholder value.
The upsized offering demonstrates strong investor demand for Jazz Pharmaceuticals debt. The company tapped qualified institutional buyers to raise the full $1.1 billion in a single tranche. This capital gives Jazz firepower for strategic investments, debt repayment, or share buybacks.
Exchangeable notes appeal to both the issuer and investors. Jazz gets lower borrowing costs at 1.875% versus traditional debt. Investors gain downside protection from the fixed interest rate while holding an option to profit if Jazz stock climbs above the conversion premium.
Jazz Pharmaceuticals provided a full and unconditional guarantee of the notes on a senior unsecured basis. This pledge strengthens the notes' credit profile for buyers. It means Jazz's general assets back the debt if the subsidiary issuer, Jazz Investments I Limited, cannot pay.
The senior unsecured status puts these notes ahead of subordinated debt in the priority queue if Jazz faces financial stress. However, secured creditors like banks holding collateral would rank higher. This structure balances investor protection with Jazz's capital structure.
Publishers
4
Articles
4
Reach
4